Listing on the Pharmaceutical Schedule of a range of orthopaedic implants and associated products with LMT Surgical Pty Ltd
5 April 2017
PHARMAC is pleased to announce the approval of a listing agreement for the supply of orthopaedic implants and associated products with LMT Surgical Pty Ltd (“LMT”).
In summary, the effect of the decision is that:
- A range of orthopaedic implants and associated products will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 May 2017.
- DHB hospitals can purchase these items directly from LMT.
- It will deliver national savings of approximately $20,000 per annum.
Details of the decision
In April 2016 an orthopaedic implants and associated products request for proposal (“RFP”) was released requesting proposals for non-exclusive national agreements for medical devices to PHARMAC for a listing on the Pharmaceutical schedule and LMT responded to this request.
The purpose of the RFP was to secure national contracts for DHB hospitals to purchase from, and to provide savings opportunities for the DHBs.
PHARMAC has entered into an agreement with LMT for the supply of a selection of orthopaedic implants and associated products to be listed on the Pharmaceutical Schedule. This means that DHB hospitals that purchase these products must do so under the national agreement at the new pricing from 1 May 2017.
The agreement is not exclusive, DHBs can continue to purchase other brands of orthopaedic implants and associated products at their discretion.
Educational services will be provided by LMT to DHB personnel on appropriate use of its orthopaedic implants and associated products and will be arranged in a format and at times as agreed with individual DHBs.
No feedback was received by 4pm 27 March 2017 in relation to this proposal.
If you have any questions about this decision, you can email us at firstname.lastname@example.org or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 July 2020